{ "brand": "CENDORYA", "study": "AXIS-1", "source": "Avenlith synthetic study dossier, AXIS-1 v1.0, tables 1–5. Invented for this demonstration.", "design": "Randomized, double-blind, placebo-controlled, parallel-group, 8-week fictional study.", "protocol": "Adults aged 30–74; seated systolic pressure 145–169 mmHg at screening; eGFR ≥60 mL/min/1.73 m². Stable background therapy permitted. Protocol criteria are invented, not clinical guidance.", "randomized": [ 300, 300 ], "analysis": [ 292, 292 ], "safety": [ 300, 300 ], "arms": [ "CENDORYA 5 mg", "Placebo" ], "primary": { "type": "continuous", "endpoint": "Change in mean seated systolic blood pressure", "unit": "mmHg", "week": 8, "values": [ -14.2, -7.1 ], "difference": -7.1, "ci": [ -9.2, -5 ], "population": "Full-analysis population: 292 per arm", "qualification": "Synthetic group means. The endpoint does not establish cardiovascular outcomes, individual response or durability beyond eight weeks.", "views": [ "chart", "table", "difference", "source" ] }, "secondary": { "type": "binary", "endpoint": "At least 10 mmHg reduction in seated systolic pressure", "week": 8, "counts": [ 164, 120 ], "denominators": [ 292, 292 ], "percentages": [ 56.2, 41.1 ], "population": "Full-analysis population: 292 per arm", "qualification": "Exploratory synthetic secondary endpoint. The protocol threshold is not a clinical treatment target. No multiplicity-adjusted inference supplied.", "views": [ "percentage", "counts", "icons", "source" ] }, "time": [ { "week": 0, "efficacy": [ 0, 0 ], "safety": null, "stopped": null, "follow": "Baseline visit. Safety surveillance begins." }, { "week": 2, "efficacy": [ -7.4, -4.3 ], "safety": null, "stopped": null, "follow": "Scheduled pressure assessment; no visit-specific safety table supplied." }, { "week": 4, "efficacy": [ -10.8, -5.7 ], "safety": null, "stopped": null, "follow": "Scheduled pressure assessment; no visit-specific discontinuation table supplied." }, { "week": 8, "efficacy": [ -14.2, -7.1 ], "safety": [ 64, 49 ], "stopped": [ 18, 15 ], "follow": "Final endpoint visit. Cumulative safety and discontinuations cover weeks 0–8." }, { "week": 12, "efficacy": null, "safety": null, "stopped": null, "follow": "Not observed in this dossier. No long-term endpoint or follow-up claim established." } ], "safetyEvents": [ { "name": "Any treatment-emergent event", "counts": [ 64, 49 ] }, { "name": "Dizziness", "counts": [ 18, 10 ] }, { "name": "Headache", "counts": [ 13, 12 ] }, { "name": "Symptomatic low blood pressure", "counts": [ 9, 3 ] }, { "name": "Serious adverse event", "counts": [ 2, 2 ] } ], "discontinuations": { "all": [ 18, 15 ], "adverse": [ 9, 4 ], "other": [ 9, 11 ] }, "scenarios": [ { "name": "Age 56 · systolic 156 · eGFR 78", "protocol": "Within these three stated protocol criteria.", "baseline": "Age 50–64, systolic 150–159 and eGFR ≥60 appear separately in the synthetic baseline table.", "subgroup": "No approved joint subgroup effect estimate supplied.", "unknown": "Representation and response for this exact combination are not established." }, { "name": "Age 79 · systolic 156 · eGFR 78", "protocol": "Outside the invented age criterion of 30–74.", "baseline": "Adults aged 75 or older were excluded.", "subgroup": "No ≥75 subgroup analysis supplied.", "unknown": "Efficacy and safety in this age scenario are not established." }, { "name": "Age 56 · systolic 156 · eGFR 42", "protocol": "Outside the invented renal criterion: eGFR must be ≥60.", "baseline": "eGFR below 60 was excluded.", "subgroup": "No renal-impairment subgroup analysis supplied.", "unknown": "This dossier cannot support extrapolation to impaired renal function." }, { "name": "Age 56 · diabetes · stable background therapy", "protocol": "Diabetes and stable background therapy permitted; all other eligibility criteria still apply.", "baseline": "Diabetes present in 22% of randomized participants, considered alone.", "subgroup": "No diabetes-specific efficacy or safety estimate supplied.", "unknown": "Aggregate prevalence does not establish joint representation or individual suitability." } ], "challenges": [ { "question": "Why this comparator?", "answer": "Placebo plus unchanged background care isolates the incremental pressure change within this invented design.", "limit": "No active-comparator study; relative performance versus another medicine is unknown." }, { "question": "What was measured?", "answer": "Mean seated systolic pressure change at week 8, from standardized repeated readings. Full-analysis population: 292 per arm.", "limit": "No cardiovascular event endpoint, ambulatory 24-hour endpoint or patient-level response prediction." }, { "question": "How uncertain is the result?", "answer": "Synthetic between-arm difference −7.1 mmHg; invented 95% confidence interval −9.2 to −5.0 mmHg.", "limit": "This interval illustrates statistical uncertainty only. It is not real clinical evidence." }, { "question": "Who was included?", "answer": "600 randomized; 584 in the full-analysis population. Adults aged 30–74 within the invented screening range and renal criterion.", "limit": "Eligibility is distinct from baseline representation and subgroup evidence. No joint subgroup analysis supplied." }, { "question": "How long was follow-up?", "answer": "Eight weeks of treatment; the primary endpoint was assessed at week 8.", "limit": "Durability, long-term safety and cardiovascular outcomes are not established." }, { "question": "A question outside this set", "answer": "Unresolved in the supplied dossier.", "limit": "Use the organization’s medical-information process in a real setting. This demo sends nothing." } ], "questions": [ { "id": "effect", "text": "What was the measured pressure change?", "page": 11 }, { "id": "population", "text": "Where does the trial evidence end?", "page": 13 }, { "id": "mechanism", "text": "How does the proposed mechanism connect?", "page": 7 }, { "id": "risk", "text": "What safety information is available?", "page": 16 }, { "id": "duration", "text": "What is established over time?", "page": 15 }, { "id": "outcomes", "text": "Were cardiovascular outcomes studied?", "page": 14, "unresolved": true } ], "bridge": [ { "title": "01 / Circulation", "label": "General physiology", "text": "The heart pumps blood through vessels; pressure reflects interacting factors, including circulating volume and vascular resistance.", "boundary": "Simplified anatomy, grounded in general cardiovascular education." }, { "title": "02 / Vessel wall", "label": "Illustrative cellular process", "text": "Smooth muscle in the arterial wall contributes to vascular tone. The animation shows structure, not a treatment response.", "boundary": "Wall movement is a schematic illustration, not a measured patient outcome." }, { "title": "03 / VTR-4 target", "label": "Hypothetical brand mechanism", "text": "The fictional molecule is imagined to modulate an invented VTR-4 vascular target.", "boundary": "VTR-4 and this molecular geometry are invented. Target engagement was not directly measured in AXIS-1." }, { "title": "04 / Clinical measure", "label": "Synthetic clinical endpoint", "text": "AXIS-1 supplies group-level seated systolic pressure change at week 8.", "boundary": "The study does not establish that the depicted molecular steps caused the observed endpoint, nor establish cardiovascular outcomes." } ] }